Sign up to save your podcasts
Or
Share The Safe and Effective Cure to Cancer: Angiex Founder Paul Jaminet Shares the Science | Ep. 32
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Safe and Effective Cure to Cancer: Angiex Founder Paul Jaminet Shares the Science | Ep. 32
In this episode of Industry Ignited, Dr. Leeanne Aguilar sits down with Paul Jaminet, Ph.D., Founder and President of Angiex, to discuss a revolutionary new approach to cancer therapy that delivers drugs directly into tumor cell nuclei while sparing healthy tissue. Drawing from his journey through MIT physics, Harvard astrophysics, software entrepreneurship, and natural health research, Jaminet shares how he and his wife, Angiex’s scientific co-founder, developed AGX-101, a TM4SF1-targeted nuclear-delivered antibody drug conjugate now in Phase 1 clinical trials. This conversation explores how physics, biology, and patient-first engineering converge to change the future of oncology and redefine how cancer can be safely and effectively treated.
View all episodes
By Leeanne Aguilar, Ph.D.In this episode of Industry Ignited, Dr. Leeanne Aguilar sits down with Paul Jaminet, Ph.D., Founder and President of Angiex, to discuss a revolutionary new approach to cancer therapy that delivers drugs directly into tumor cell nuclei while sparing healthy tissue. Drawing from his journey through MIT physics, Harvard astrophysics, software entrepreneurship, and natural health research, Jaminet shares how he and his wife, Angiex’s scientific co-founder, developed AGX-101, a TM4SF1-targeted nuclear-delivered antibody drug conjugate now in Phase 1 clinical trials. This conversation explores how physics, biology, and patient-first engineering converge to change the future of oncology and redefine how cancer can be safely and effectively treated.